Publications by authors named "Thibault Raoult"
Article Synopsis
- - Biomarkers are necessary to optimize the use of immune-checkpoint blockers (ICB) like pembrolizumab for patients with localized muscle-invasive bladder cancer (MIBC), as highlighted by the study on T cells and immune responses.
- - The research identified follicular helper CD4+ T cells (TFH) and specific antibodies against E. coli as potential biomarkers that correlate with better clinical outcomes for patients receiving pembrolizumab treatment.
- - Understanding the connections between tumor infections and immune responses can lead to improved therapeutic strategies and better patient management in the future.
Article Synopsis
- The study investigated the feasibility, safety, and effectiveness of intratumoural (IT) immunotherapy in 100 patients, aiming to address resistance and reduce side effects associated with traditional immune checkpoint therapies.
- Researchers documented a variety of patient and tumor characteristics, with most injections targeting superficial lymph nodes and skin lesions, and noted that 72% of patients also received systemic immunotherapy.
- Adverse events occurred in 11.3% of treatment cycles, with mostly mild severity, while response rates showed 5% complete and 18% partial responses, particularly among patients receiving HIT-IT as a first-line treatment.
Article Synopsis
- Human intratumoral immunotherapy (HIT-IT) is rapidly evolving and showing promising results in phase III trials, focusing on the technical aspects of drug injection for effective treatment outcomes.
- Image-guided access to tumors enhances drug concentration directly at the site while reducing systemic exposure and potential side effects, making it a safer option.
- The article emphasizes the importance of patient selection, accurate lesion assessment, and standardized workflows to optimize the effectiveness and experience of patients undergoing HIT-IT.
Systemic immunotherapies such as immune checkpoint blockade targeted at PD(L)1 and CTLA4 have demonstrated their ability to provide durable tumor responses and long-term overall survival benefits for some patients in several solid tumor types. However, a majority of patients remain resistant to these treatments and a significant proportion of them develop severe autoimmune and inflammatory adverse events. Preclinical studies have demonstrated that intratumoral injections of immunostimulatory products (oncolytics, pattern recognition receptor agonists,…) that are able to trigger type I IFN release and enhance tumor antigen presentation on immune cells could generate a strong antitumor immunity and overcome the resistance to systemic immune checkpoint blockade therapies.
View Article and Find Full Text PDF